WO2006035681A1 - HLA-A11拘束性Tax抗腫瘍エピトープ - Google Patents
HLA-A11拘束性Tax抗腫瘍エピトープ Download PDFInfo
- Publication number
- WO2006035681A1 WO2006035681A1 PCT/JP2005/017527 JP2005017527W WO2006035681A1 WO 2006035681 A1 WO2006035681 A1 WO 2006035681A1 JP 2005017527 W JP2005017527 W JP 2005017527W WO 2006035681 A1 WO2006035681 A1 WO 2006035681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- htlv
- peptide
- inducing
- hla
- amino acid
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 141
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims abstract description 98
- 230000001939 inductive effect Effects 0.000 claims abstract description 79
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims abstract description 47
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 31
- 229960005486 vaccine Drugs 0.000 claims abstract description 23
- 238000012360 testing method Methods 0.000 claims abstract description 22
- 230000028993 immune response Effects 0.000 claims abstract description 20
- 230000036737 immune function Effects 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 65
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 42
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 32
- 239000004480 active ingredient Substances 0.000 claims description 26
- 239000000863 peptide conjugate Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000000032 diagnostic agent Substances 0.000 claims description 17
- 229940039227 diagnostic agent Drugs 0.000 claims description 17
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 13
- 239000000562 conjugate Substances 0.000 claims description 9
- 230000000735 allogeneic effect Effects 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 44
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 abstract description 33
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 abstract description 33
- 201000006966 adult T-cell leukemia Diseases 0.000 abstract description 33
- 239000000427 antigen Substances 0.000 abstract description 21
- 102000036639 antigens Human genes 0.000 abstract description 21
- 108091007433 antigens Proteins 0.000 abstract description 21
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 238000000338 in vitro Methods 0.000 abstract description 7
- 230000004044 response Effects 0.000 abstract description 5
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 3
- 238000009630 liquid culture Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 20
- 230000006698 induction Effects 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- -1 hexaphosphoroamide Chemical compound 0.000 description 9
- 108010075704 HLA-A Antigens Proteins 0.000 description 8
- 102000011786 HLA-A Antigens Human genes 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 101900141355 Human T-cell leukemia virus 1 Protein Tax-1 Proteins 0.000 description 7
- 108010004729 Phycoerythrin Proteins 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010080347 HLA-A*26 antigen Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 108700026241 pX Genes Proteins 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 108010038751 tax Gene Products Proteins 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 108010091373 HA-1 antigen Proteins 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- ZUSSTQCWRDLYJA-UHFFFAOYSA-N n-hydroxy-5-norbornene-2,3-dicarboximide Chemical compound C1=CC2CC1C1C2C(=O)N(O)C1=O ZUSSTQCWRDLYJA-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- HLA_Al 1 restricted Tax antitumor epitopes
- the present invention is directed to induce cytotoxic T cells (CTL) having an antitumor effect against human T cell leukemia virus type I (HTLV-I) tumors such as adult T cell leukemia (ATL).
- CTL cytotoxic T cells
- HTLV-I human T cell leukemia virus type I
- ATL adult T cell leukemia
- the present invention relates to HTLV-I-specific CTL-inducing active peptides, DNA encoding the peptides, vaccines for inducing immune responses using these, immune function test diagnostic agents, and the like.
- ATL is a T-cell malignancy that affects approximately 5% of people infected with human T-cell leukemia virus type I (HTLV-I), mainly CD4 + and CD25 + mature T lymphocyte phenotypes It is characterized by having onset, middle-aged or later onset, immunosuppression, and poor prognosis (for example, see Non-Patent Documents 1 and 2;). Although the 4-year survival rate has increased to 8-12% due to clinical use of chemotherapy combined with ATL, it is still low compared to other types of leukemia (eg, Non-patent Document 3, See 4;). More recently, hematopoietic stem cell transplantation (HSCT) has been applied to some ATL patients.
- HSCT hematopoietic stem cell transplantation
- Allogeneic HSCT received from siblings with human leukocyte antigen (HLA) has been shown to cause some GVHD, and the recipient's minor histocompatibility antigen (mHA) has been considered the target antigen for GVHD.
- HLA human leukocyte antigen
- mHA minor histocompatibility antigen
- HTLV-I Host cell-mediated immune responses to HTLV-I, particularly cytotoxic T-cell proliferation, are found in patients with asymptomatic HLTV-1 carrier and HTLV I-associated myelopathy Z tropical spastic paraplegia (HAM / TSP). Forces frequently found in PBMC cultures Rarely seen in ATL patients (eg, see Non-patent Documents 17 and 18) 0 HTLV-I antigens such as env, gag, pol, and pX gene products Among them, the pX gene product Tax is known to be a dominant target antigen of HTLV-I-specific cytotoxic lymphocytes (CTL) (see, for example, Non-Patent Documents 19 and 20).
- CTL cytotoxic lymphocytes
- Tax also plays a key role in leukemia of the HTLV I by promoting cell growth suppressing apoptosis that have known (e.g., non-Patent Document 21, 22 references.) 0 or more Tax-specific CTL plays a role in immunological monitoring of leukemia in HTLV I-infected cells It has been suggested that may be.
- the present inventors have already found a major epitope of CTL restricted by human HLA-A2 (see, for example, Non-Patent Document 23). Only 40% are positive.
- the present inventors have clarified the antitumor effect of Tax-specific CTL in vivo (for example, Patent Document 1, Non-patent document 1). See Patent Documents 24 and 25.) 0
- fresh T cells are transplanted from syngeneic immunocompetent rats that have been vaccinated with either a DNA encoding Tax or a peptide corresponding to a CTL epitope.
- Non-patent document 1 Int. J. Cancer 45, 237-243, 1990; Blood 50, 481-492, 1977
- Non-patent document 2 Proc. Natl. Acad. Sci. USA 78, 6476-6480, 1981
- Non-Patent Document 3 J. Clin. Oncol 6, 128-141, 1988
- Non-Patent Document 4 J. Clin. Onco 6, 1088-1097, 1988
- Non-Patent Document 5 Bone Marrow Transplant 23, 87-89, 1999
- Non-Patent Document 6 Bone Marrow Transplant 27, 15-20, 2001
- Non-Patent Document 7 N. Engl. J. Med. 334, 281-285, 1996
- Non-Patent Document 8 Science 269, 1588-1590, 1995
- Non-Patent Document 9 Science 279, 1054-1057, 1998
- Non-Patent Document 10 N. Engl. J. Med. 334, 286-291, 1996
- Non-Patent Document 11 Br. J. Haematol 106, 723-729, 1999
- Non-Patent Document 12 Blood 92, 2169-2176, 1998
- Non-Patent Document 13 Blood 75, 552-562, 1990
- Non-Patent Document 14 Blood 93, 2336-2341, 1999
- Non-Patent Document 15 Blood 95, 1781-1787, 2000
- Non-Patent Document 16 Blood 96, 1480-1489, 2000
- Non-Patent Document 17 Leukemia 8 Suppl 1, S54-59, 1994
- Non-Patent Document 18 J. Immunol. 133, 1037-1041, 1984
- Non-Patent Document 19 Nature 348, 245-248, 1990
- Non-Patent Document 20 Int. Immunol. 3, 761-767, 1991
- Non-Patent Document 21 Lancet 1, 1085-1086, 1987
- Non-Patent Document 22 J. Virol. 73, 7981-7987, 1999
- Non-Patent Document 23 J. Virol. 66, 2928-2933, 1992
- Non-Patent Document 24 J. Virol. 74, 428-435, 2000
- Non-Patent Document 25 J. Virol. 73, 6031-6040, 1999
- Non-Patent Document 26 J. Virol. 74, 9610-9616, 2000;
- Non-Patent Document 27 J. Natl. Cancer Inst. 93, 1775-1783, 2001
- Non-Patent Document 28 Gann 73, 341-344, 1982
- Non-Patent Document 29 Int. J. Cancer 54, 582-588, 1993
- Non-Patent Document 30 Proc. Natl. Acad. Sci. USA 86, 5620-5624, 1989
- ATL is a neoplastic disease caused by infection with HTLV-I, which has a high prevalence in Japan, but it has been regarded as a malignant tumor with a very poor prognosis because it is resistant to chemotherapeutic agents. .
- HTLV-I Tax It has a power. Therefore, it is necessary to specify a CTL recognition epitope in order to develop more specific and safer cytokines.
- CTL epitopes with anti-tumor effects have been identified and have been successful.
- An object of the present invention is to provide an HTLV-I-specific CTL-inducing peptide capable of inducing CTLs having an antitumor effect against HTLV-I tumors such as ATL, DNA encoding these peptides, and these
- the purpose is to provide a vaccine for inducing immune response using anti-tumor and a diagnostic agent for antitumor immunity test.
- the present inventors have found that PBMC after HSCT actually responds to recipient-derived cells. However, the majority of responding cells responded strongly to HTLV-I antigens, particularly to a limited number of Tax epitopes. These observations also revealed that a graft versus HTLV-I response occurred in ATL patients after HSCT. In the course of such research, we found two major epitopes of CTL bound by HLA-A11 and completed the present invention.
- the present invention relates to (1) an HTLV I-specific CTL inducing peptide having an amino acid sequence ability represented by SEQ ID NO: 3 or 4, or (2) an amino acid sequence represented by SEQ ID NO: 3 or 4, HTLV-I-specific CTL-inducing peptide consisting of an amino acid sequence in which several amino acids are deleted, substituted or added, or (3) HT LV-I-specific CTL induction as described in (1) or (2) above A fusion peptide in which an active peptide is bound to a marker protein and Z or a peptide tag, or (4) HLA-Al 1 and an HTL V-I-specific CTL-inducing peptide described in (1) or (2) above.
- a bound protein-peptide conjugate (5) a tetramer of a protein-peptide conjugate in which HLA-Al 1 and the HTLV-I-specific CTL-inducing peptide described in (1) or (2) above are bound, (6) The protein peptide conjugate according to the above (4) or the claim 5 A fusion protein in which a tetramer of protein-peptide conjugate is bound to a marker protein and Z or a peptide tag, or (7) DNA encoding the following peptide (a) or (b).
- an HTLV-I-specific CT L-inducing peptide having an amino acid sequence ability in which one or several amino acids are deleted, substituted or added, 8) DNA comprising the nucleotide sequence shown in SEQ ID NO: 7 or 8 or a complementary sequence thereof, or (9) Hybridizing with the DNA described in 8 above under stringent conditions and HTLV-I specific CTL inducing activity It relates to DNA encoding peptides.
- the present invention also relates to (10) an HLA-Al1-restricted Tax epitope comprising an HTLV-I-specific CTL-inducing peptide having an amino acid sequence represented by SEQ ID NO: 3 or 4, (11) SEQ ID NO: 3 Or an immune response-inducing vaccine containing an HTLV-I-specific CTL-inducing activity peptide consisting of the amino acid sequence shown in 4 as an active ingredient, or (12) 1 or a number in the amino acid sequence shown in SEQ ID NO: 3 or 4 An immune response-inducing vaccine containing, as an active ingredient, an HTLV-I-specific CTL-inducing peptide consisting of an amino acid sequence in which a single amino acid has been deleted, substituted or added, (13) (7) to ( 9) An immune response induction kit containing as an active ingredient a vector capable of expressing the DNA of any one of A vaccine for inducing an immune response according to any one of the above (8) to (10), further comprising an adjuvant
- the present invention provides (18) an immunological function test diagnostic agent containing a vector capable of expressing the DNA described in any of (7) to (9) as an active ingredient, and (19) HLA-A11 and An immunological function test diagnostic agent containing a tactaku peptide conjugate bound to the HTLV-I-specific CTL-inducing active peptide described in (1) or (2) above as an active ingredient, or (20) HLA-Al 1 and An immunological function test diagnostic agent comprising as an active ingredient a tetramer of a protein-peptide conjugate bound to the HTLV-I-specific CTL-inducing peptide described in (1) or (2) above, (21) 7) to (9) HTLV-I tumor diagnostic agent containing any of the DNAs described in the above as an active ingredient, or (22) HTLV-I-specific CTL-inducing activity described in (1) or (2) above An antibody that specifically binds to a peptide, (23) the antibody according to (22) above, wherein the antibody is a monoclonal antibody,
- FIG. 1 shows CTL induction on ILT # 156 cells in PBMC of patient # 156 (FIG. 1) after HSCT.
- the amount of IFN-y in the supernatant was measured by ELISA analysis. The value is the average of the test results of two samples.
- FIG. 2 is a graph showing Tax-specific cytotoxic activity of HTLV-I of CTL derived from patient # 156 after HSCT.
- the PBMC culture of patient # 156 was stimulated 3 times with formalin-fixed ILT— # 156, and its cytotoxicity was investigated by 51 Cr release analysis for 6 hours.
- the target cells used were ILT— # 156 ( ⁇ ), LCL— # 156 ( ⁇ ), HCL—All, TCL—Kan (A) and LCL—Kan (A), and HLA. — ALT ILT Nkz-2 (country) and LCL Nkz (mouth).
- Black symbols represent HTLV-I infected cells and white symbols represent EBV infected cells. Values represent the mean of cytotoxicity (% Lysis) assayed on 3 samples.
- FIG. 3 is a diagram showing the result of mapping 1111 ⁇ 1 111 ⁇ ⁇ -8 11-restricted tax epitopes recognized by CTL derived from patient # 156 after HSCT.
- LCL- # 156 cells were pulsed with 36 types of synthetic oligopeptides 15 to 24 bases long corresponding to the amino acid sequence covering the entire 10 mM Tax protein, and after HSCT as the effector, patient # 156CTL (cultured 31 days) and target cells The mixture was mixed at a ratio of 10: 1 and incubated for 18 hours, and then IFN-y in the supernatant was measured by ELISA analysis. The value is the average of the test results of two samples.
- FIG. 1 is a diagram showing the result of mapping 1111 ⁇ 1 111 ⁇ ⁇ -8 11-restricted tax epitopes recognized by CTL derived from patient # 156 after HSCT.
- LCL- # 156 cells were pulsed with 36 types of synthetic oligopeptides 15 to 24 bases
- LCL # 156 cells were pulsed with 10mM of the 9 base length synthetic oligopeptide, and the effector patient after HSCT # 156CTL (cultured for 41 days) was mixed with the target cell ratio of 10: 1 and incubated for 18 hours Thereafter, IFN-y in the supernatant was measured by ELISA analysis.
- TCL—Kan and LCL—Kan are patients # 156 and HLA—All, and ILT—Nkz-2 and LCL—Nkz are patients # 156 and HLA—A26. The value is the average of the test results of two samples.
- PBMCs stimulated with ILT— # 156 were treated with HLA—A * 110lZTax88-96 or HLA—A * 110lZTax272-280 tetramer (phycoerythrin labeled, vertical axis) and CD8 (PE-Cy5 The results of double staining with a label (horizontal axis) and flow cytometry analysis are shown.
- Patient # 156 PBMC culture medium after HSCT was cultured for 41 days. The number in the upper right indicates the percentage of PBMC that binds to the tetramer and is CD8 positive. Each case shows 100,000 phenomena in total.
- the HTLV-I specific CTL-inducing activity peptide of the present invention is an amino acid represented by SEQ ID NO: 3 or 4.
- peptide having sequence ability or in the amino acid sequence shown in SEQ ID NO: 3 or 4, amino acid sequence ability in which one or several amino acids are deleted, substituted or added, and CTL-inducing activity specifically in HTLV-I
- the peptide is not particularly limited as long as it has a peptide (hereinafter referred to as a peptide consisting of the amino acid sequence shown in SEQ ID NO: 3 or 4 and in these amino acid sequences, one or more amino acids are substituted, deleted or appended).
- the present peptides Peptides that have been modified by sputum and have CTL-inducing activity specifically for HTLV-I may be referred to as “the present peptides”), where “1 ⁇ Amino acid sequence in which several amino acids have been deleted, substituted or added '' refers to, for example, 1 to 20, preferably 1 to 15, more preferably 1 to 10, still more preferably 1 to 5 Any number of amino acids Means an amino acid sequence deleted, substituted or added, and the degree of amino acid “substitution, deletion or addition” and the position thereof are shown in SEQ ID NO: 3 or 4 for the modified peptide.
- a peptide having the above characteristics are included regardless of the cause and means of such modification / mutation.
- a peptide having an amino acid sequence ability represented by SEQ ID NO: 1 or 2 including the amino acid sequence represented by SEQ ID NO: 3 or 4 can be exemplified.
- the peptides of the present invention can be produced by chemical or genetic engineering techniques.
- the chemical method includes peptide synthesis methods using ordinary liquid phase methods and solid phase methods. More specifically, in this peptide synthesis method, based on amino acid sequence information, each amino acid is sequentially linked one by one to extend the chain, and the stepwise erosion method and a fragment consisting of several amino acids are obtained. It includes a fragment 'condensation method in which each fragment is subjected to a coupling reaction in the following manner.
- the synthesis of peptides having the amino acid sequence shown in SEQ ID NO: 3 or 4 of the present invention can also be due to deviation.
- the condensation method employed in the peptide synthesis can also follow various known methods. Specific examples include the azide method, mixed acid anhydride method, DCC method, active ester method, redox method, DPPA (diphenylphosphoryl azide) method, DCC + additive (1-hydroxybenzotriazole). N-hydroxysuccinamide, N-hydroxy 5-norbornene-2,3 dicarboximide, etc.), Woodward method and the like. Solvents that can be used in each of these methods can be appropriately selected from general solvents that are well known to be used in this kind of peptide condensation reaction.
- Examples thereof include dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexaphosphoroamide, dioxane, tetrahydrofuran (THF), ethyl acetate and the like, and mixed solvents thereof.
- DMF dimethylformamide
- DMSO dimethyl sulfoxide
- THF tetrahydrofuran
- ethyl acetate examples thereof include dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hexaphosphoroamide, dioxane, tetrahydrofuran (THF), ethyl acetate and the like, and mixed solvents thereof.
- amino acids that are not involved in the reaction and carboxyl groups in the peptide are generally esterified, for example, lower alkyl esters such as methyl ester, ethyl ester, tertiary butyl ester, for example, Benzyl It can be protected as stealth, p-methoxybenzyl ester, p-nitrobenzyl ester aralkyl ester, and the like.
- An amino acid having a functional group in the side chain may be protected with a acetyl group, a benzyl group, a benzyloxycarbonyl group, a tertiary peptide group, etc. There is no need to provide protection.
- Ar g of a guazino group includes a nitro group, a tosyl group, a 2-methoxybenzenesulfol group, a methylene-2-sulfol group, a benzyloxycarbonyl group, an isobornoxycarboxyl group, It can be protected with a suitable protecting group such as a damantoxycarbonyl group.
- the deprotection reaction of these protecting groups in the amino acids having the above-mentioned protecting groups, peptides, and finally obtained peptides of the present invention can also be carried out by conventional methods such as catalytic reduction, liquid ammonia Z sodium, It can be carried out according to a method using hydrogen fluoride, hydrogen bromide, hydrogen chloride, trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid or the like.
- the peptides of the present invention can also be produced by a conventional method using genetic engineering techniques.
- the peptides of the present invention thus obtained can be obtained according to conventional methods, for example, ion exchange resin, partition chromatography, gel chromatography, affinity chromatography, high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- any marker protein may be used as long as the peptide, marker protein, and Z or peptide tag are bound to each other.
- marker proteins include alkaline phosphatase, antibody Fc region, HRP, GFP, and the like, and peptide tags such as HA, FLAG, Myc, etc.
- peptide tags such as HA, FLAG, Myc, etc.
- affinity tags such as GST, maltose binding protein, pyotinylated peptide, oligohistidine and the like can be given.
- Such fusion peptides can be prepared by conventional methods.
- the protein-peptide conjugate of the present invention is not particularly limited as long as it is a conjugate of HLA-All and the present peptides.
- HLA-Al 1 molecule and SEQ ID NO: 3 or 4 are shown.
- Preferred is a form capable of binding to CTL that recognizes a strong conjugate, such as a conjugate with a peptide having high amino acid sequence ability.
- the tetramer of the protein-peptide conjugate of the present invention is not particularly limited as long as it is a tetramer of a protein-peptide conjugate in which HLA-All and the peptides are bound,
- the protein-peptide conjugate can be exemplified as a tetramer with streptavidin as a nucleus.
- a substrate of the enzyme Bir-A is expressed at the C-terminus of HLA-A11, and Bir -A-depe ndent ⁇ 1 ⁇ 2 can be obtained by mixing 4 ⁇ 1 with 111 ⁇ ⁇ -8-11 and phycoerythrin (PE) -labeled glycosylated avidin (Altaian, JD, et al .: Science 274, 94-96, 1996).
- PE phycoerythrin
- These protein-peptide conjugates and their tetramers consist of the chemically synthesized peptides, the HLA-All gene (accession number P13 746) and the ⁇ -2 microglobulin gene (accession number ⁇ _004048).
- HLA—Al l a domain and ⁇ 2 microglobulin prepared by a conventional method using genetic engineering techniques that utilize the protein are bound in vitro in a refolding buffer (Garboczi et al. Proc. Natl Acad. Sci. USA., 89: 3429-3433, 1992), or genetic engineering techniques using DNA encoding the peptides and the HLA—Al 1 gene and ⁇ 2 microglobulin gene, respectively.
- the peptide and the HLA-all alpha domain and j8-2 microglobulin are co-expressed in the same host cell using conventional methods, and these are combined after purification.
- the fusion protein of the present invention may be any protein as long as the protein-peptide conjugate or protein-peptide conjugate tetramer is bound to the marker protein and Z or peptide tag.
- the marker protein is not particularly limited as long as it is a conventionally known marker protein.
- Specific examples of the marker protein include fluorescent dyes, alkaline phosphatase, antibody Fc region, HRP, and GFP.
- Specific examples of peptide tags include epitope tags such as HA, FLAG, and Myc, and conventionally known peptide tags such as affinity tags such as GST, maltose binding protein, pyotiny peptide, and oligohistidine. Can do.
- Such a fusion tongue The compounds can be prepared by conventional methods. Purification of protein-peptide conjugates using the affinity between Ni-NTA and His tags, detection of CTLs, and other research reagents in this field. Is also useful.
- antibodies that specifically bind to the peptides of the present invention include immunospecific antibodies such as monoclonal antibodies, polyclonal antibodies, chimeric antibodies, single-chain antibodies, and humanized antibodies. These are the powers that can be prepared by conventional methods using the peptides of the present invention as an antigen. Among them, monoclonal antibodies are more preferred in terms of their specificity.
- Antibodies that specifically bind to the peptides, such as strong monoclonal antibodies are HTLV-I specific for the peptides that are useful for diagnosis of HTLV-I tumors such as ATL. This is useful for clarifying the CTL induction activity mechanism and molecular mechanism.
- An antibody against the peptides of the present invention can be obtained by using a conventional protocol in an animal (preferably other than human) to the peptides, the complex of the peptides and an immunogenic protein,
- a conventional protocol in an animal preferably other than human
- the high-pridoma method (Nature 256, 495-) is used to produce antibodies produced by continuous cell line cultures. 497, 1975)
- Trioma method (Immunology Today 4, 72, 1983)
- EBV—hybridoma method MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp.77-96, Alan R. Liss, Inc. , 1985) can be used.
- the DNA of the present invention includes a DNA encoding the peptide of the present invention, and a sequence (encoding an HTLV-I-specific CTL inducing peptide having amino acid sequence shown in SEQ ID NO: 3 or 4). It hybridizes under stringent conditions with DNA having the nucleotide sequence shown in No. 7 or 8 or its complementary sequence, or DNA consisting of the nucleotide sequence shown in No. 7 or 8 or its complementary sequence.
- the DNA of the present invention is not particularly limited as long as it encodes an HTLV-I-specific CTL-inducing peptide (hereinafter referred to as “the present DNA group” in some cases).
- the above-mentioned conditions for ⁇ under the stringent conditions, ibridize '' are, for example, a hybridization at 42 ° C and a buffer solution containing 1 X SSC, 0.1% SDS at 42 ° C.
- Cleaning process Raised More preferred examples include hybridization at 65 ° C., and washing treatment at 65 ° C. with a buffer containing 0.1 X SSC and 0.1% SDS.
- DNA groups of the present invention include, for example, the nucleotide sequence represented by SEQ ID NO: 5 or 6 (which encodes an HTLV-I-specific CTL-inducing peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 or 2) It also includes DNA with complementary sequence ability.
- the DNA group of the present invention can be advantageously used when the peptides are produced by a conventional method using genetic engineering techniques.
- the antisense strand of the DNA group of the present invention is an ATL or the like. It is useful as a diagnostic probe for HTLV-I tumors.
- the HLA-All-restricted Tax epitope of the present invention is an HTLV-I-specific CTL having the amino acid sequence shown in SEQ ID NO: 3 or 4 above, capable of inducing CTL in vivo. It is not particularly limited as long as it is an epitope composed of an inducing active peptide.
- the peptides including the HLA-Al 1-restricted Tax epitope and vectors capable of expressing the DNA groups are used in the immune response-inducing vaccines of the present invention such as cellular immunity and humoral immunity. It can be used as an active ingredient.
- the vaccine for inducing immune response according to the present invention can be used for the treatment of HTLV-I tumors such as ATL.
- the vaccine for inducing immune response of the present invention it is more preferable to use various adjuvants that enhance cellular or local immunity.
- Specific examples include QS21 (commercially available from Quillaia sa ponaria, Cambridge Biotech, Worcester, MA), aluminum hydroxide, aluminum phosphate, aluminum oxide, oily emulsion, saponin, vitamin E lysate, etc. be able to.
- the pharmaceutical composition of the present invention containing the above-mentioned vaccine for inducing immune response of the present invention as an active ingredient contains a pharmaceutically acceptable carrier or diluent, an immunostimulant, an additive and the like.
- a pharmaceutically acceptable carrier or diluent examples include, for example, stabilizers such as SPGA, carbohydrates such as sorbitol, mannitol, starch, sucrose, glucose, dextran, proteins such as albumin and casein, and the like.
- Specific examples include protein-containing substances such as rabbit serum and skim milk, and buffer solutions such as phosphate buffer, physiological saline and water.
- the immunostimulant include site force-in such as interleukin-1 (IL-2), interleukin-12 (IL-12), tumor necrosis factor a (THF-s), Additives include low molecular weight polypeptides (less than about 10 residues), proteins, carbohydrates containing amino acids, glucose or dextran, chelating agents such as EDTA, protein stabilizers, microbial growth inhibitors or inhibitors, etc.
- site force-in such as interleukin-1 (IL-2), interleukin-12 (IL-12), tumor necrosis factor a (THF-s)
- Additives include low molecular weight polypeptides (less than about 10 residues), proteins, carbohydrates containing amino acids, glucose or dextran, chelating agents such as EDTA, protein stabilizers, microbial growth inhibitors or inhibitors, etc.
- chelating agents such as EDTA, protein stabilizers, microbial growth inhibitors or inhibitors, etc.
- the present invention is not limited to these examples.
- the pharmaceutical composition of the present invention is preferably in a form that can be administered orally, intravenously, intraperitoneally, intranasally, intradermally, subcutaneously, intramuscularly, and the like.
- the effective amount to be administered can be appropriately determined in consideration of the type and composition of the pharmaceutical product or pharmaceutical composition, the administration method, the age and weight of the patient, etc., and these are administered once to several times a day. It is preferable.
- When administered orally it is usually administered in the form of a preparation prepared by mixing with a pharmaceutical carrier.
- a carrier that can be used in the preparation a substance that is commonly used in the pharmaceutical field and does not react with the peptide of the present invention is used.
- dosage forms include tablets, capsules, condyles, powders, syrups, suspensions, suppositories, ointments, creams, gels, patches, inhalants, injections, etc.
- These preparations can be prepared according to conventional methods, and in the case of liquid preparations in particular, they can be dissolved or suspended in water or other suitable medium at the time of use. Tablets and granules may be coated by a known method. In the case of injection, it is prepared by dissolving the peptide of the present invention in water, but it may be dissolved in physiological saline or glucose solution if necessary, and a buffer or preservative may be added. Also good. These preparations may also contain other components having therapeutic value.
- the peptides of the present invention are used as a food material for preventing infection with HTLV-I and ameliorating symptoms of Z or HTLV-I related diseases, such as pudding, cookies, bread, cakes, jellies, rice crackers, etc.
- Japanese sweets such as confectionery, sheep crab, bread confectionery such as frozen confectionery, chewing gum, confectionery such as udon and soba, fish paste products such as power mackerel, ham, and fish sausage, chocolate, drink yogurt, juice , Milk, soy milk, alcoholic beverages, coffee, tea, sencha, oolong tea, sports beverages, miso, soy sauce, dressing, mayonnaise, sweeteners, tofu, konjac, other boiled and dumplings , Croquettes, salads, etc. can be blended into various side dishes and taken as functional foods.
- the immune function test diagnostic agent of the present invention includes the peptide, the vector capable of expressing the DNA group, the protein peptide conjugate in which HLA-Al1 and the peptide are bound, or the It is not particularly limited as long as it has a tetramer of protein-peptide conjugate as an active ingredient and can test and diagnose immune function, particularly immune function against HTLV-I.
- a radioisotope can be used in addition to the marker protein and peptide tag described above.
- the peripheral blood leukocytes (lymphocytes) of the subject are contacted with the immune function test diagnostic agent of the present invention, and epitopes in the peptides etc. are recognized.
- HTLV-I Tax specific T cells can be identified by binding to T cells.
- fluorescent labels such as the above-mentioned protein-peptide conjugate tetramer PE enable the detection and quantification of CTLs by flow cytometry. This is particularly useful for determining vaccine efficacy.
- a mononuclear cell fraction is isolated from a heparin peripheral blood sample, and a PE-labeled tetramer (tetramer of protein-peptide conjugate) and an active marker antibody such as CD8 antibody labeled with FITC or PE-Cy5.
- a PE-labeled tetramer tetramer of protein-peptide conjugate
- an active marker antibody such as CD8 antibody labeled with FITC or PE-Cy5.
- the expression vector of the present invention may be any peptide that can express the peptide or a conjugate of HLA-A11 (a domain and Z or j8-2 microglobulin) and the peptide.
- any expression system that can express the peptides of the present invention in cells can be expressed from chromosomes, episomes, and viruses.
- a vector derived from the combination of a string for example, a plasmid such as cosmidyaphamidimide and a butterio
- a plasmid such as cosmidyaphamidimide and a butterio
- these viral-based vectors are preferred.
- These expression systems may contain control sequences that regulate expression as well as cause expression.
- an expression vector series that can be translated by changing the reading frame can be advantageously used.
- the expression vector of the present invention is useful as an active ingredient in the immune response-inducing vaccine of the present invention.
- the host cell of the present invention includes the present peptides and an expression system capable of expressing a conjugate of HLA-A11 (a domain and Z or j8-2 microglobulin) and the present peptides.
- Host cells that can be used as long as they are cells include bacterial prokaryotic cells such as E.
- coli Streptomyces, Bacillus subtilis, Streptococcus and Staphylococcus
- eukaryotic cells such as yeast and Aspergillus, Insect cells such as S2, Spodoptera Sf9, L cells, CHO cells, COS cells, HeLa cells, C127 cells, BALBZc3T3 cells (including mutants lacking dihydrofolate reductase or thymidine kinase), BH Examples thereof include animal and plant cells such as K21 cells, HEK293 cells, Bowes melanoma cells, and oocytes.
- expression systems capable of expressing the peptides are introduced into host cells by Davis et al.
- the method for inducing HTLV-I-recognizing CTLs of the present invention includes using HTLV-I-infected T cells derived from an ATL patient before HSCT, and using the same type of HLA type, ie, HLA-All type donor. Stimulate PBMC of the same patient after HSCT in vitro, in vivo or ET vivo. Using this method to induce CTL, stimulate PBMC of HLA—All positive ATL patients in vitro, in vivo or ET vivo.
- HTLV-I recognition Using HLA-A11-positive methods such as CTL induction methods and vectors capable of expressing the DNA group in this way, such as expressing peptides in antigen-presenting cells in PBMC by genetic engineering.
- Stimulating PBMC in ATL patients in vitro, in vivo, or in vivo, HTLV—I recognition CTL obtained by a powerful induction method is not particularly limited if it is a method of induction of HTLV—I recognition CTL.
- it is useful for clarifying the activation mechanism and molecular mechanism of HTLV-I-specific CTL induction.
- A-1 (Recipient Z donor combination and blood sample)
- Peripheral blood samples were obtained from acute ATL patients who received HSCT, as well as donors from HLA-matched sibling donors. The patient achieved complete remission 3 months after HSCT and has since maintained it. Henone-treated blood was collected 147 days after transplantation, and peripheral blood mononuclear cells (PBMC) were isolated by Huycol 'Hypack Plus gradient centrifugation, and a portion was liquid until use. Stored with body nitrogen.
- PBMC peripheral blood mononuclear cells
- A-2 (cell line)
- ILT # 156 an HTLV-I-infected T cell line derived from a pre-HSCT patient, was established by the following procedure. After removing CD8 + cells from PBMC, stimulate with 1 ⁇ g Zml of magtinin (PHA) —P followed by 10% heat-inactivated fetal calf serum (FCS) and 30 U / ml of recombinant human IL— It was maintained in RPMI-1640 medium containing 2 or lOngZml of recombinant human IL-15 at 37 ° C for 2 months or more with 5% carbon dioxide.
- LCL # 156 an Epstein's virus (EBV) transformed B cell line, was established in vitro from donor CD19 + PBMC infected with the supernatant of B95-8 cells containing EBV.
- EBV Epstein's virus
- A-3 Induction of HTLV-I-specific CTL
- PBMC rich in whole patient cells or CD8 + cells after HSCT stimulated with 1 ⁇ g Zml ⁇ - ⁇ , then mixed with the same number of ILT # 156 cells pretreated with 1% formaldehyde ZPBS did.
- ILT # 156 cells pretreated with 1% formaldehyde ZPBS did.
- T cells are maintained in AIM-V TM medium (GIBCO-Invitrogen) supplemented with 10% FCS and lOOUZml recombinant human IL-2, and periodically ILT- # every 14 days. Stimulation was given with 156 cells.
- the present inventors prepared a peptide having a length of 15 to 24 bases in order to cover the entire sequence of Tax protein of HTLV-I.
- BIMA S http: bimas.dcrt.nih.gOv/molbil/hla#bind/
- a computer prediction program was published in the literature (J. Immunol. 152, 163-175, 19 94; Immunol. 152, 3913-3924, 1994) was used to prepare a 9-base long HTLV-I Tax peptide that could bind to HLA-A11.
- 51 Cr release analysis was performed for 6 hours at various effector cell to target cell (EZT) ratios to determine cytotoxic activity. Specific cytotoxicity was calculated according to the formula ([ 51 Cr release obtained spontaneously 51 Cr released] Z [maximum 51 Cr released spontaneous 51 Cr released] X 100%).
- ELISA Hito IFN-y ELISA kit, Biosource, Camarillo, California
- the tetramer is NIAID Tetramer Facility, Emory Univ. Vaccine and entrusted synthesis to enter at Yerks (Atlanta, Georgia).
- Lymphocytes were stained with PE-Cy5-conjugated anti-CD8 anti-monoclonal antibody (BD Pharmingen) for 30 minutes, then with tetramer for another 60 minutes at 4 ° C, then CellQuest Two-color analysis was performed with FAC SCal3 ⁇ 4ur using software (Beckton Dickinson).
- ILT- # 156 a T cell line, was established. This cell line was positive for CD4 and positive for HTLV-I antigens such as HTLV-I Tax and pl9.
- T cell responses in patients' PBMCs after HSCT to ILT- # 156 cells were examined 147 days after HSCT when hematopoietic cells were completely replaced by donor-derived hematopoietic cells.
- IFN-y is produced against allogeneic HTLV-I-infected TCL- Kan cells that share HLA-A11.
- LCL-Kan shares HLA-A11
- HTLV-1 infected ILT shares HLA-A26.
- -No IFN-y was produced for Nkz-2 or LCL-Nkz.
- B- 2 (HTLV-I specificity of CTL that also induced patient power after HSCT)
- PBMC strength of patients after HSCT was also examined by 51 Cr release assay for cytotoxicity of effector cells grown against ILT- # 156.
- effector cells are almost force SCD8 positive, exhibit a significant level of cytotoxicity against ILT- # 156 ( Figure 2), and are allogeneic HTLV-I infected TCL- Kan Although the cells were killed effectively, they were not killed by LCL—Kan, which shares HLA-A11, and HTLV-I, ILT—Nkz-2 and LCL—Nkz, which share HLA-A26.
- HTLV-I antigen-specific CD8 + cytotoxic T lymphocytes CTLs
- HLA-A11 cytotoxic T lymphocytes
- oligopeptides 15-24 bases in length was used to examine the recognition epitope of patient-derived CTL lines after HSCT.
- LCL # 156 cells pulsed with oligopeptides Tax 81-104 (QRTSKTLKVLTPPITHTTP NIPPS; SEQ ID NO: 1) and Tax271-285 (LQSSSFIFHKFQTKA; SEQ ID NO: 2) are selectively killed by the patient's CTL line after HSCT ( Figure 3).
- Tax 88-96 KVLTPPITH; SEQ ID NO: 3
- Tax272-280 QSSSFIFHK; SEQ ID NO: 4
- Tax 88-96 includes Tax 81-104, Tax 272-280 ⁇ and Tax271-285, which is included!
- the above results show that two types of HTLV-I Tax-specific CTL clones dominate the patient-derived CTL line after HSCT, and one of the CTL clones is HLA-All-restricted.
- a sex Tax88-96 epitope showing that another CTL clone recognizes the HLA—All-restricted Tax272-280 epitope.
- HLA Tax epitope
- CT L for the epitope identified by the present invention is selectively Induced. This means that this epitope was strongly expressed in the patient, indicating that this epitope is useful as a vaccine antigen.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006537705A JP5176099B2 (ja) | 2004-09-27 | 2005-09-22 | HLA−A11拘束性Tax抗腫瘍エピトープ |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-280649 | 2004-09-27 | ||
JP2004280649 | 2004-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006035681A1 true WO2006035681A1 (ja) | 2006-04-06 |
Family
ID=36118828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/017527 WO2006035681A1 (ja) | 2004-09-27 | 2005-09-22 | HLA-A11拘束性Tax抗腫瘍エピトープ |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5176099B2 (ja) |
WO (1) | WO2006035681A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020246535A1 (ja) * | 2019-06-05 | 2020-12-10 | 国立大学法人 東京医科歯科大学 | Htlv-i特異的ctl活性化剤 |
WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人t細胞白血病の治療又は予防のための医薬組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507397A (ja) * | 1998-03-13 | 2002-03-12 | エピミューン,インコーポレイティド | Hla結合ペプチド及びその使用 |
WO2004092373A1 (ja) * | 2003-04-16 | 2004-10-28 | Japan Science And Technology Agency | Htlv-i特異的ctl誘導活性ペプチド |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635363A (en) * | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
JP3536039B2 (ja) * | 2001-05-08 | 2004-06-07 | 独立行政法人 科学技術振興機構 | Htlv−i腫瘍に対する抗腫瘍抗原又はその抗原エピトープ |
-
2005
- 2005-09-22 WO PCT/JP2005/017527 patent/WO2006035681A1/ja active Application Filing
- 2005-09-22 JP JP2006537705A patent/JP5176099B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507397A (ja) * | 1998-03-13 | 2002-03-12 | エピミューン,インコーポレイティド | Hla結合ペプチド及びその使用 |
WO2004092373A1 (ja) * | 2003-04-16 | 2004-10-28 | Japan Science And Technology Agency | Htlv-i特異的ctl誘導活性ペプチド |
Non-Patent Citations (5)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020246535A1 (ja) * | 2019-06-05 | 2020-12-10 | 国立大学法人 東京医科歯科大学 | Htlv-i特異的ctl活性化剤 |
WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人t細胞白血病の治療又は予防のための医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006035681A1 (ja) | 2008-05-15 |
JP5176099B2 (ja) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7524930B2 (en) | Tumor antigen | |
JP4422903B2 (ja) | 癌抑制遺伝子wt1の産物に基づく癌抗原 | |
CA2600898C (en) | Novel cancer antigen peptide and the use thereof | |
WO2003006632A2 (en) | Methods and compisitions for activation human t cells in vitro | |
JP4779067B2 (ja) | HLA−A2402拘束性Ep−CAM特異的CTLが認識するエピトープ・ペプチド及びその用途 | |
Kawashima et al. | Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells | |
WO2006106912A1 (ja) | 癌関連抗原アナログペプチド、およびその利用 | |
US20050267020A1 (en) | Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same | |
EP1805214A2 (en) | T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use | |
US20060111551A1 (en) | Peptide having HTLV-1-specific CTL-inducing activity | |
JP5176099B2 (ja) | HLA−A11拘束性Tax抗腫瘍エピトープ | |
JP5999703B2 (ja) | HLA−DR1拘束性Tax特異的CD4+T細胞エピトープ | |
WO2018032501A1 (zh) | 一种新的肿瘤特异性多肽及其应用 | |
JP3536039B2 (ja) | Htlv−i腫瘍に対する抗腫瘍抗原又はその抗原エピトープ | |
JPH1070986A (ja) | ヒトTh1特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 | |
EP4067371A1 (en) | T-cell receptors specific for hepatitis c virus peptides | |
MX2011005944A (es) | Peptidos de epitope wdrpuh y vacunas que los contienen. | |
JPWO2003008450A1 (ja) | 腫瘍抗原 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006537705 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |